Physician profile
James E New
NPI 1518951037
$1,705.52
in general payments reported to CMS, 2019-2025
13 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $134 · 2021: $104 · 2022: $320 · 2023: $208 · 2024: $337 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $553.96 | 2022-2025 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $269.46 | 2019-2025 | Rocklatan, Precision7, Eysuvis |
| Coopervision INC. | $200.44 | 2019-2025 | Biofinity Contact Lens, Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $194.59 | 2019-2023 | |
| Dompe US, INC. | $144.92 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $79.79 | 2020-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $73.53 | 2019-2021 | |
| Biotissue Holdings INC. | $62.10 | 2020-2025 | |
| Tarsus Pharmaceuticals, INC. | $61.77 | 2024 | Xdemvy |
| Amgen INC. | $19.51 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $18.35 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $14.03 | 2019 | |
| Allergan, INC. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James New listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.